Table 1.
Patient characteristics at baseline.
| Characteristics | Number of patients (%) (N = 285) |
|---|---|
| Median age (years, range) | 50 (26–87) |
| ECOG PERFORMANCE-STATUS SCORE | |
| 0 | 78 (27.3) |
| 1 | 193 (67.7) |
| 2 | 14 (5.0) |
| HORMONE RECEPTOR STATUS | |
| HR positive | 115 (40.4) |
| HR negative | 170 (59.6) |
| DISEASE-FREE INTERVAL | |
| Primary metastatic | 69 (24.2) |
| DFI ≤ 1year | 71 (25.0) |
| DFI > 1year | 145 (50.9) |
| METASTATIC SITES | |
| Lung | 112 (39.3) |
| Liver | 107 (37.5) |
| Bone | 119 (41.8) |
| Brain | 69 (24.2) |
| NUMBER OF METASTATIC SITES | |
| 1 | 77 (27.0) |
| 2 | 91 (32.0) |
| ≥3 | 117 (41.1) |
| VISCERAL METASTASES | |
| Yes | 209 (73.3) |
| No | 76 (26.7) |
| LINES OF ADVANCED SYSTEMATIC THERAPY OF TLC | |
| 1 | 65 (22.8) |
| 2 | 80 (28.1) |
| ≥3 | 140 (49.1) |
| TRASTUZUMAB RESISTANCE STATUS | |
| Resistance | 118 (41.4) |
| Refractoriness | 133 (46.7) |
| Unknown | 28 (10.0) |
| PRIOR HER2-TARGETED THERAPY | |
| Trastuzumab | 253 (88.8) |
| Lapatinib | 52 (18.2) |
| T-DM1 | 15 (5.3) |
| Pertuzumab | 2 (0.7) |
HR, Hormone receptor; ECOG, Eastern Cooperative Oncology Group; DFI, Disease free interval; TLC, trastuzumab+ lapatinib+ chemotherapy.